---
title: "AXSM.US (AXSM.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AXSM.US/news.md"
symbol: "AXSM.US"
name: "AXSM.US"
parent: "https://longbridge.com/en/quote/AXSM.US.md"
datetime: "2026-05-20T20:51:33.479Z"
locales:
  - [en](https://longbridge.com/en/quote/AXSM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AXSM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AXSM.US/news.md)
---

# AXSM.US (AXSM.US) — Related News

### [Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch](https://longbridge.com/en/news/286164148.md)
*2026-05-12T22:08:12.000Z*
> Axsome Therapeutics is set to launch AUVELITY for Alzheimer’s disease agitation in June, while also expanding its effort

### [Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions](https://longbridge.com/en/news/286077483.md)
*2026-05-12T10:11:29.000Z*
> Axsome Therapeutics has received FDA approval for AUVELITY, the first treatment for agitation associated with Alzheimer'

### [Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating](https://longbridge.com/en/news/285765329.md)
*2026-05-08T18:46:10.000Z*
> Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) stock, raising the

### [3 Stocks Poised to Disrupt the Healthcare Market by 2030](https://longbridge.com/en/news/285719882.md)
*2026-05-08T12:00:19.000Z*
> Three companies are set to disrupt the healthcare market by 2030: Tempus AI, Recursion Pharmaceuticals, and Axsome Thera

### [Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/285520861.md)
*2026-05-07T09:34:04.000Z*
> Oppenheimer & Co. Inc. has acquired a new position in Axsome Therapeutics, purchasing 7,076 shares valued at approximate

### [Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock](https://longbridge.com/en/news/285297559.md)
*2026-05-06T02:17:01.000Z*
> Axsome Therapeutics COO Mark Jacobson sold 233 shares of stock at an average price of $228.18, totaling $53,165.94. Post

### [3 Overlooked Stocks Set to Soar in 2026](https://longbridge.com/en/news/285214574.md)
*2026-05-05T13:15:25.000Z*
> Three overlooked biotech stocks, Axsome Therapeutics, NovoCure Limited, and MBX Biosciences, are poised for growth by 20

### [Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)](https://longbridge.com/en/news/285188644.md)
*2026-05-05T10:38:23.000Z*
> Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) with a price targe

### [Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target](https://longbridge.com/en/news/285176899.md)
*2026-05-05T08:55:52.000Z*
> Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, raising the price target